Skip to main content

Table 1 (abstract P10). Number (%) of pts with pcJIA achieving JADAS LDA ± normal function with tofacitinib vs PBO in Part 2

From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)

 

Tofacitinib

N=72

PBO

N=70

p value

Tofacitinib

N=72

PBO

N=70

p value

 

cJADAS10 LDA

JADAS10-CRP LDA

W18

34 (47.2)

32 (45.7)

0.857

35 (48.6)

33 (47.1)

0.861

W24

32 (44.4)

21 (30.0)

0.072

34 (47.2)

24 (34.3)

0.114

W44

34 (47.2)

22 (31.4)

0.051

34 (47.2)

23 (32.9)

0.077

 

cJADAS10 LDA + normal function

JADAS10-CRP LDA + normal function

W18

17 (23.6)

20 (28.6)

0.501

17 (23.6)

20 (28.6)

0.501

W24

23 (32.0)

14 (20.0)

0.101

24 (33.3)

15 (21.4)

0.108

W44

26 (36.1)

13 (18.6)

0.017

25 (34.7)

14 (20.0)

0.046